Laparoscopic Sleeve Gastrectomy-Induced Decline in Plasma Asprosin and Its Association With Metabolic Recovery

NCT07008274 | Completed

• 1 other identifier: NorthernJiangsu123
• Study Type: observational
• Target: 85
• Locations: 1 country
• Sites: 1

Brief Summary

the present study aimed to systematically assess the changes in plasma asprosin levels at 3, 6, and 12 months after LSG, to explore the relationships between asprosin dynamics and key metabolic parameters, including body mass index (BMI), fasting glucose, insulin resistance assessed by the homeostasis model (HOMA-IR), and lipid profiles, and to compare asprosin concentrations between bariatric patients and healthy normal-weight controls.

Conditions

Obesity, Morbid

Keywords

bariatric surgery; asprosin

Outcome Measures

Primary Outcomes (1)

• Plasma asprosin levels at 3, 6, and 12 months

  1 year

Secondary Outcomes (1)

• BMI at 3, 6, and 12 months

  1 year

Other Outcomes (1)

• Insulin resistance (HOMA-IR) at 3, 6, and 12 months

  1 year

Study Arms (1)

surgery

surgery

Procedure: surgery

Interventions

surgery PROCEDURE

laparoscopic sleeve gastrectomy

surgery

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults with obesity (BMI ≥37.5 kg/m², or ≥32.5 kg/m² with metabolic comorbidities such as type 2 diabetes, hypertension, or dyslipidemia), aged 18-65 years, undergoing laparoscopic sleeve gastrectomy at a single tertiary hospital in China. Healthy normal-weight controls (BMI 18.5-23.9 kg/m²) without metabolic disorders were also recruited for baseline comparison.

You may qualify if:

• age between 18 and 65 years;
• body mass index (BMI) ≥37.5 kg/m², or BMI ≥32.5 kg/m² with at least one obesity-related comorbidity;
• availability of complete clinical data and stored plasma samples at preoperative baseline and at 3, 6, and 12 months postoperatively.

You may not qualify if:

• history of prior bariatric or gastrointestinal surgery;
• active malignancy, chronic inflammatory or infectious disease, or severe hepatic or renal dysfunction;
• pregnancy during the study period;
• incomplete clinical or biochemical data.

Sponsors & Collaborators

• Northern Jiangsu People's Hospital: lead

Study Sites (1)

Shuai Zhao

Yangzhou, None Selected, 225001, China

Location

MeSH Terms

Conditions

Obesity, Morbid; Arachnodactyly

Interventions

Surgical Procedures, Operative

Condition Hierarchy (Ancestors)

Obesity; Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Limb Deformities, Congenital; Musculoskeletal Abnormalities; Musculoskeletal Diseases; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director

Study Record Dates

• First Submitted: May 11, 2025
• First Posted: June 6, 2025
• Study Start: January 1, 2021
• Primary Completion: January 31, 2025
• Study Completion: January 31, 2025
• Last Updated: June 6, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)